Kadmon — Investor Presentation (March 2017)
34 slides from Kadmon's investor presentation, Mar 8, 2017
Slide 1: Kadmon Corporate Presentation
8 Kadmon Corporate Presentation
Slide 2: Forward-looking Statement
Forward-looking Statement This presentation contains “forward-looking” statements that are based on the beliefs and assumptions and on information currently available to management of Kadmon Holdings, Inc. (the ‘Company’. All statements other than statements of historical fact contained in this pres
Slide 3: Company Highlights
Company Highlights Diverse, Science-driven Clinical Pipeline Leader in R&D of ROCK Inhibitors Biologics Platform D025: ROCK2 inhibitor — In Phase 2 for moderate to severe psoriasis — In Phase 2 for idiopathic pulmonary fibrosis — In Phase 2 for chronic graft-versus-host disease Tesevatinib: Brain-pe
Slide 4: Innovative Pipeline for Major Significant Medical Needs
Innovative Pipeline for Major Significant Medical Needs Preclin. | Phase 4 Clinical Stage Compounds | Indication Moderate to Severe Psoriasis > (RocK2 | |“opathic Pulmonary Fibrosis a, A (IPF) Chronic Graft-Versus-Host | Disease (CGVHD) NSCLC with Brain Metastases ue, or Leptomeningeal Disease Oncol
Slide 5: ROCK Inhibitor Platform
ROCK Inhibitor Platform Autoimmune, Fibrotic and Neurodegenerative Diseases
Slide 6: Kadmon's Target: Rho-associated Protein Kinase (ROCK)
Kadmon’s Target: Rho-associated Protein Kinase (ROCK) Kadmon is Develo; lors for Several Diseases ig Oral Selective ROCK In! e ROCK is a moleculartarget with substantial therapeutic potential across multiple disease areas: — Autoimmune diseases — Fibrotic diseases — Neurodegenerative diseases ¢ TwoR
Slide 7: Kadmon's Lead ROCK Inhibitor: KD025
Kadmon’s Lead ROCK Inhibitor: KDO25 KD025, an Oral Selective ROCK2 Inhibitor in Phase 2 Developmer e Eight completed Phase 1 and Phase 2 clinical studies of KD025 in more than 180 subjects, in doses rangingfrom 20 mg to 1,000 mg; KD025 was well tolerated across all studies — Phase 1 safety data in h
Slide 8: Kadmon has Defined a Key Role of ROCK2 in Autoimmune Disease
Kadmon has Defined a Key Role of ROCK2 in Autoimmune Disease ROCK2 inhibition with KD025 down-regulates the pro-inflammatory response while potentially avoiding limitations of current biologic therapies, including increased risk of serious infections and malignancies Autoimmune Disease * Autoimmunit
Slide 9: KD025 Inhibits Th17 Cytokine Secretion in Healthy Human Cells
KD025 Inhibits Th17 Cytokine Secretion in Healthy Human Cells (in vitro analysis) KD025 Down-Regulates Secretion of Th17 Inflammatory Cytokines Ir 124 22 5 08 as 4 - 04 ve: as 03 z Eos £ 22 3 302 1 a2 o4 ° ° ° o 42° 25 5 Ot o 42 28 5 | 0 o 42 28 5 | > > > 0025 (ul) 0025 (ul) 0025 (uM) No Deleterious
Slide 10: KD025 in Psoriasis: PASI Score Improvement in 85% of Patients
KD025 in Psoriasis: PASI Score Improvement in 85% of Patients Patients Completing Phase 2 Study of KD025in Psoriasis Who Achieved PASI 50 42% 71% (6/12 patients) (6/7 patients) i Month 2, Day 4 Hi onth 2, bay 1 I Ena of Treatment % of Patients Achieving PASI50 400 mg QD 200 mg BID Completed Phase 2,
Slide 11: KD025: Ongoing Phase 2 Study in Psoriasis
KD025: Ongoing Phase 2 Study in Psoriasis Market Size: Moderate to Severe Psoriasis e Psoriasis affectsas many as 7.5 million people in the United States e Need fornovel oral agents that lack gastrointestinal side effects Continued Development of KD025 in Moderateto Severe Psoriasis e Ongoing, rando
Slide 12: ROCK Plays Key Role in Fibrotic Disease
ROCK Plays Key Role in Fibrotic Disease e Fibrosisis a consequence of aberrant wound-healing — Prolonged activation of myofibroblasts can result in permanent scarring, organ malfunction and death e ROCK is key common pathway and therapeutic target for pathologic fibrosis — ROCK inhibition reduces co
Slide 13: ROCK Mediates Multiple Pro-Fibrotic Processes
ROCK Mediates Multiple Pro-Fibrotic Processes Lung Fibrosis Progression KD025 targets these specific processes Cell Type Pathophysiology + TGF activation + Expression of CTGF + Paracellular gap [| « Fibroblast + Contractile gene formation differentiation to [| expression myofibroblast [J + Collagen
Slide 14: KD025 Attenuates Pulmonary Fibrosis in Bleomycin-Induced Mouse Model
KD025 Attenuates Pulmonary Fibrosis in Bleomycin-Induced Mouse Model Intratracheal Bleomycin KD025 treatment administered when + fibrosis is already established | comeeniimmmen (orally, 50, 100 or 150 mg QD) 1 Vehicle or KDO25 Day 8 Intratracheal Bleomycin Day 0
Slide 15: KD025 in Fibrotic Disease: Ongoing Clinical Study
KD025 in Fibrotic Disease: Ongoing Clinical Study Market Size: Idiopathic Pulmonary Fibrosis 128,000 people in the United States are living with IPF, with 48,000 newcases diagnosed annually Median survival after IPF diagnosis is approximately 2-3 years KD025: Ongoing Study in Idiopathic Pulmonary Fi
Slide 16: KD025: Ongoing Phase 2 Study in cGVHD
KD025: Ongoing Phase 2 Study in cGVHD cGVHD Background e cGVHDis a commonand often fatal complication following allogeneic stem cell transplantation — Transplanted immune cells attack recipienttissue, leading to fibrosis in the lung, Gl tract, liver and skin — ROCK signaling pathway regulates IL-21
Slide 17: Tesevatinib
Tesevatinib Oncology and Polycystic Kidney Disease
Slide 18: Tesevatinib: A Unique Tyrosine Kinase Inhibitor for Oncology
Tesevatinib: A Unique Tyrosine Kinase Inhibitor for Oncology Tesevatinib: Distinguishing Characteristics e Oral, reversible and highly potent EGFR inhibitor — Alsoinhibits VEGFR2, HER2 and Src family kinases e Highly blood-brain barrier penetrant: 1:1 brain/blood ratio — Compared to <0.15:1 brain/bl
Slide 19: NSCLC Study: Encouraging Results in First Patients
NSCLC Study: Encouraging Results in 11 of First 13 Patients Ongoing Phase 2 Study in NSCLC with Brain Metastases or Leptomeningeal Disease « NSCLC patients with activating EGFR mutations receiving tesevatinib 300 mg QD: — Brain metastases (BM) (third-line treatment) — Leptomeningeal metastases (LM)
Slide 20: NSCLC Study: Patient With BM and LM Sees Improvement
NSCLC Study: Patient With BM and LM (034-002) Sees Improved Right Parieto-Occipital Leptomeningeal Enhancement 20
Slide 21: NSCLC Study: Patient With BM Sees ~50% Overall Decrease
NSCLC Study: Patient With BM (045-003) Sees ~50% Overall Decrease in Brain Metastases 21
Slide 22: Tesevatinib: Clinical Plan in NSCLC with CNS Metastases
Tesevatinib: Clinical Plan in NSCLC with CNS Metastases Market Size: EGFR-Mutant NSCLC with CNS Metastases e NSCLC with activating EGFR mutations with brain metastases or leptomeningeal metastases —- EGFR activating mutations occur in ~20% of NSCLC patients in the United States — ~50% of tumors driv
Slide 23: Tesevatinib: Exploratory Study in Glioblastoma
Tesevatinib: Exploratory Study in Glioblastoma Tesevatinib in Glioblastoma Ongoing exploratory Phase 2 study of tesevatinib in recurrent glioblastoma — Glioblastomais a primary brain tumor and represents a major unmet medical need — EGFR gene abnormalities are commonin glioblastomas: + >50% of gliom
Slide 24: Tesevatinib: Polycystic Kidney Disease Pathophysiology
Tesevatinib: Polycystic Kidney Disease Pathophysiology Tesevi uniquely po: e Most prevalent monogenic disease with no approved therapies inthe U.S. — 600,000 PKD patients in U.S.; 12.5 million worldwide — Autosomal dominant PKD (ADPKD) presents in adulthood — Autosomal recessive PKD (ARPKD) presents
Slide 25: Tesevatinib: Effective in PKD Rat and Mouse Models
Tesevatinib: Effective in PKD Rat and Mouse Models Vehice Tesevatnb —Tesevatin Nome Gpeased—Tesevsin) Tesevatnt ‘7.Smgikg/day —1Emg/ka/day 7.Smgikgiday —1Smghkalday ‘15mg/kg/day
Slide 26: Tesevatinib in ADPKD: Ongoing Study and Clinical Plan
Tesevatinib in ADPKD: Ongoing Study and Clinical Plan Ongoing, Open-Label, Dose-Finding Phase 2a Study: Safety and Tolerability at 50 mg QD Study initiated in 2012; 61 patients enrolled « No drug-related SAEs ¢ No significant increase in kidney size; no change in kidney function e New data supportte
Slide 27: Tesevatinib in ARPKD: Clinical Plan
Tesevatinib in ARPKD: Clinical Plan ARPKOD: Planned Phase1 Study ¢ Tesevatinib reformulated for liquid dosing e Developmental toxicology completed Planned Phase 1, ascending single-dose safety study of tesevatinib in ARPKD patients ages 5 to 12 « Two clinical sites selected Three cohorts planned (te
Slide 28: KD034 Portfolio
KD034 Portfolio Wilson’s Disease
Slide 29: KD034: Enhanced Formulations of Trientine for Wilson's Disease
KD034: Enhanced Formulations of Trientine for Wilson’s Disease Kadmon is Developing Convenient Forms of Wilson’s Disease Therapies e Wilson’s Disease: Orphan genetic liver disease, major unmet medical need — 10,000 living with Wilson’s Disease in the United States — Requires lifelong treatment — Cur
Slide 30: Preclinical Programs
Preclinical Programs
Slide 31: Kadmon: Preclinical Pipeline
Kadmon: Preclinical Pipeline Near-Term Immuno-Oncology Collaboration Opportunity * Lead candidate: KD035, an anti-VEGFR2 antibody being developed for anti-angiogenesis indications * Also developing KD033, a unique anti-PD-L1/IL-15 fusion protein * Completed biologics licensing agreement with Jinghua
Slide 32: Multiple Data Readouts Expected Throughout 2017 and 2018
Multiple Data Readouts Expected Throughout 2017 and 2018 [Product ——_|indication 2017 2018 Tesevatnib = iaaaaaaaaal | | s (Oncology) . a qesevatnib: Autosomal Dominant (AD) PKD* O Ld is) ‘Autosomal Recessive (AR) PKD* | a | Moderate to Severe Psoriasis gq ROCK2 Inhibitor , rem cat yop lopathic Pulmo
Slide 33: Company Highlights
Company Highlights KD025: ROCK2 inhibitor — In Phase 2 for moderate to severe psoriasis — In Phase 2 for idiopathic pulmonary fibrosis — In Phase 2 for chronic graft-versus-host disease Tesevatinib: Brain-penetrant EGFR inhibitor that accumulates in leptomeninges and kidneys — In Phase 2 for NSCLC w
Slide 34: Financial Profile
Financial Profile KDMN Fi Summary e Kadmon completed its IPO on August 1, 2016; gross proceeds of $75mm e 45,078,666 common shares outstandingas of November8, 2016 e Trades onthe NYSE under the ticker symbol “KDMN” e Revenue of $21.8mm for the nine months ended September 30, 2016 KDMN LISTED NYSE